A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer

  • McCartney, Amelia (Primary Chief Investigator (PCI))
  • Day, Daphne (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date16/11/21 → 15/11/26

Keywords

  • phase 1 study
  • breast cancer
  • treatment efficacy
  • treatment safety